Actively Recruiting
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous Non-Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy in Brazil
Led by AstraZeneca · Updated on 2026-05-22
250
Participants Needed
11
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are conducting a retrospective, noninterventional study to review medical records of patients diagnosed with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have received systemic treatment after failing platinum-based chemotherapy. This study includes patients with or without actionable genomic alterations (AGA) and aims to describe the patient population and treatment patterns between January 2017 and December 2024. Subgroup analyses will be performed on specific NSCLC subtypes, such as EGFR mutant, ALK translocation, and others if sample size allows. The study involves reviewing records of patients who have failed platinum-based chemotherapy and immunotherapy (for non-AGA patients) or platinum-based chemotherapy and at least one line of targeted therapy (for AGA patients). The index date is defined as the first dose of any agent after platinum chemotherapy failure. The study covers one cohort regardless of AGA status and includes analysis of various NSCLC genetic subtypes. There is no intervention or treatment administered as part of this observational study. Participants' medical records will be examined to collect data on diagnosis, treatments received, and outcomes. The primary outcome is to describe patient characteristics and treatment patterns over the defined period. Since this is a retrospective review, no active participation or treatment is required from patients. The study is expected to be completed by June 2026, with data collection focusing on routine clinical practice and outcomes after platinum chemotherapy failure.
CONDITIONS
Brief Title
RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of advanced or metastatic non-squamous NSCLC stage IIIB/IIIC not eligible for curative therapies or stage IV/M1 with or without actionable genomic mutations
- Age 18 years or older at first diagnosis of advanced/metastatic NSCLC
- For patients with actionable genomic alterations, must have received platinum-based chemotherapy and at least one approved targeted therapy
- For patients without actionable genomic alterations, must have received sequential or concurrent immunotherapy and platinum-based chemotherapy
- Must have received at least one line of active therapy after failing platinum-based chemotherapy
You will not qualify if you...
- Patients with other primary cancers (except basal cell carcinoma and melanoma) within one year before index date
- Patients who participated in any investigational clinical trial or early access program for cancer treatment from 2018 onward
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Data collected from January 1st, 2017 to December 31st, 2024
Participants who have previously received standard treatments for advanced non-squamous NSCLC are observed through retrospective medical record review to assess treatment patterns and outcomes.
No visits; data are collected retrospectively from medical records
Trial Site Locations
Total: 11 locations
1
Research Site
Belo Horizonte, Minas Gerais, Brazil, 30110-934
Not Yet Recruiting
2
Research Site
Belo Horizonte, Minas Gerais, Brazil, 30380-420
Not Yet Recruiting
3
Research Site
Natal, Rio Grande do Norte, Brazil, 59062-000
Actively Recruiting
4
Research Site
Porto Alegre, Rio Grande do Sul, Brazil, 90560-032
Not Yet Recruiting
5
Research Site
São José do Rio Preto, São Paulo, Brazil, 15090-000
Not Yet Recruiting
6
Research Site
São Paulo, Brazil, 01308-050
Actively Recruiting
7
Research Site
São Paulo, Brazil, 01323-001
Not Yet Recruiting
8
Research Site
São Paulo, Brazil, 01323-020
Actively Recruiting
9
Research Site
São Paulo, Brazil, 01333-010
Actively Recruiting
10
Research Site
São Paulo, Brazil, 01509-010
Not Yet Recruiting
11
Research Site
São Paulo, Brazil, 05652-900
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here